Market Positioning Stock Market Investments Market Trends Venture Capital Investment Market Trends Corporate Finance Leadership Changes Revenue
The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.